

A message for providers

New Baby, New Life[™]

When it comes to our pregnant members, we are committed to keeping both mom and baby healthy. That's why we encourage our moms-to-be to take part in our New Baby, New LifeSM program, a comprehensive case management and care coordination program

that offers:

- Support on an individualized, one-on-one case management basis for women at the highest risk
- Care coordination for moms who may need a little extra support
- Educational materials and information on community resources
- Rewards for keeping up with prenatal and postpartum checkups and well-child visits after the baby is born

Here at BlueCross BlueShield of Western New York (BlueCross BlueShield), we partner with providers and moms to ensure all medical and resource needs are met, aiming for the best possible outcomes for both moms and babies.

How it works

Once we identify a pregnant member through notification from your office, state enrollment files, claims data, lab reports, etc., we enroll her in the program and perform a risk assessment to determine the level of case management support needed throughout the pregnancy. Some moms benefit from tips on eating the right foods, exercising or obtaining referrals to local agencies; others who have had prior preterm births or who have chronic health conditions, such as diabetes or high blood pressure, may need extra help.



www.bcbswny.com/stateplans

Learning how to stay healthy

The program supports moms:

- From the start. We supply all our pregnant moms with information to promote the best outcomes by starting with the basics. We even offer rewards to moms who keep their prenatal and postpartum care visits; moms may receive up to 750 points (\$75 value) that they can redeem from the Healthy Rewards catalog. Please note that a member can receive no more than \$125 within one 12-month period.
- Throughout pregnancy. Members are enrolled into My Advocate™, a program that provides innovative health communications. My Advocate promotes regular doctor visits and general health education throughout the pregnancy and postpartum period with automated telephone outreach, text messaging or via the My Advocate smartphone application.
- We encourage our pregnant members to sign up for the Text4Baby[™] program. Text4Baby is a service at no extra cost. Moms can receive text messages, in English or Spanish, with friendly reminders about health promotion activities and helpful tips about staying healthy and preparing for delivery. Members can visit text4baby.org to sign up or text "BABY" (for Spanish, BEBE) to 51411.
- Postpartum. The member receives information on self-care and care for the newborn after giving birth.

Prior preterm pregnancy program Meeting our members' special needs

When we identify a member at risk for having a second premature infant, our case managers notify you and provide you with information on 17-alphahydroxyprogesterone caproate (17P) therapy. For more information on the benefits of 17P and how to obtain it, contact your Provider Relations representative.

Group support

We work directly with the Centering Healthcare Institute to promote and encourage providers to adopt the CenteringPregnancy® model of care. This model of care:

- Allows participants to experience their prenatal care visits in a group setting with other pregnant women of a similar gestational age
- Encourages women to educated, motivate and support each other as they experience similar changes to their bodies and their lifestyles in general

We also partner with the Nurse-Family Partnership program, where available, to give extra care to our members having their first babies. A nurse visits the member throughout her pregnancy and until the baby is 2 years old, providing education, community assistance and support.

You and Your Baby in the NICU

The Neonatal Intensive Care Unit (NICU) can be a frightening place for parents, and we are here to help. You and Your Baby in the NICU is our program designed to help parents cope with the day-to-day stress, teach them about staying involved in the care of their babies, and help them prepare themselves and their homes for discharge.

Other resources

We are here to support you, our pregnant members and their little ones on the way. If you need assistance:

- Our case managers are here to help you. If a member in your care could benefit from case management, please call us at 1-866-231-0847.
- Members can call our 24/7 NurseLine at 1-866-231-0847.

We collaborate with community agencies and programs to connect members with local resources, including Women, Infants and Children, Social Services, public housing and child care agencies. Want more information about our obstetric case management program? Call your Provider Relations representative.

This model has resulted in positive outcomes, including increased birth weight.

A division of HealthNow New York Inc., an independent licensee of the Blue Cross and Blue Shield Association.



Phone: (716) 887-8734 FAX: (716) 887-7913

Medicaid Phone: (866) 231-0847 Medicaid FAX: (844) 812-2276







February 2018



WNY COLLABORATIVE PRENATAL CARE RISK SCREENING and REFERRAL FORM

Member Last Name _____ Member First Name _____ Member ID #: _____

Street Address:			City:		_ State:	Zip:	
Home Phone:	_//	Work/Cell pho	one:	//	DOB:	//	YYYY
PNC Provider Infor				_ First Name: _			
Address:					Provider ID	#:	
Tax ID #:		Phone:/	/	Provider F	AX:/	/	_
		_ Gestational Age (we	eeks)	by LM	IP OR Dby U	ltra sound	
Entry into PNC	Gravida:	Para: LM	IP/_	/	EDC	// M DD YY	
Height	Weight	Pre-preg		DD ҮҮҮҮ ЛІ	M	M DD YY	ΥΥ
Demographic inf	formation: Ch	noose ALL that app	ply.				
	☐Caucasian ☐English	☐Black or African A ☐Spanish ☐C	merican				
		all risk factors tha					
Prior Current Abdominal surg C-Section Cervical incomp Placenta Abrupt Placenta Previa	petence		cs lbs bs	Prior Current Fetal abnor Multiple ge HTN/Preec Gestational STDs	estation lampsia Diabetes	Prior Current	er or > 35 ession nol use use
		risk factors that a					
Yes On Meds Anemia Asthma Auto-Immune d Cardiac history			bolism	Yes On Meds Hypertensio Kidney disc Thyroid disc Seizures	ease	Unde	g disorder
		eck all risk factors					
Unmarried/NO parti No family support Unstable housing Homeless No phone	☐ Husband ☐ Educatio	/partner unemployed n<12 yrs tation problem	Sexual Physic Risk o	al abuse	☐ Unplanned pre☐ Children in for☐ Language barr	ster care	On Meds ☐ Psychiatric diagnosis
		s taken by the prov			ed by the pati		
Yes Refused Community Cas Health Plan Cas Behavioral/ Met Domestic Violen	se Manager e Manager ntal Health	ss Refused		Yes Refused Asthma Edi Diabetes Ed Home Visit Supplemen	ducator	Other	
		vith linkage or referral to e or referral of your pat		?			
Name: Provider comp	leting form	Date:	·	Practitioner Signa	ature or office sta	ımp:	
Current Pregnancy R	isk: High	At-Risk Lov	v				
NYWPEC-078	32-18		L			February 201	10

Candidates for 17 alpha-hydroxyprogesterone caproate (17P)

To support your efforts in preventing preterm delivery in high-risk pregnant women, BlueCross BlueShield of Western New York (BlueCross BlueShield) is launching a program to ensure providers are aware of members who may benefit from administration of 17P. You will receive an alert listing members on your panel identified through our high-risk screening survey as potential candidates for 17P.

Prescriptions and administration

If you wish to prescribe 17P for your patient, we offer the following guidance on how you may obtain 17P for delivery and administration:

- For office administration of 17P, prior authorization (PA) is required.
 - Refer to Clinical Utilization Management Guideline CG-Drug-19 for PA criteria at www.bcbswny.com/stateplans.
 - Complete the attached Makena (Hydroxyprogesterone Caproate Injection) Outpatient prior authorization form and fax it to 1-800-454-3730 or call 1-844-487-9292.
 - Once PA is obtained, fax the prescription and a copy of the member's ID card to Accredo Specialty Pharmacy at 1-800-824-2642 or call in the prescription to 1-800-870-6419.
- For home health administration, a separate PA is required.
 - Refer to Clinical Utilization Management Guideline CG-MED-23 for PA at www.bcbswny.com/stateplans.
 - Prior to requesting home health administration of 17P, verify that 17P has been approved.

About 17P

Preterm birth (delivery before 37 weeks and zero/seven days of gestation) is a leading cause of infant morbidity and mortality in the United States. For women who have had a spontaneous preterm delivery, the risk for preterm delivery in subsequent pregnancies is 1.5 to 2 times higher. For pregnant women with a singleton pregnancy and a history of spontaneous preterm delivery, 17P can reduce the risk of preterm birth by approximately 30%.

The U.S. Food and Drug Administration approved hydroxyprogesterone caproate injections to reduce the risk of preterm delivery in pregnant women with a history of prior preterm birth. As with any drug, there are risks that may outweigh these benefits.

If you have questions, please contact Provider Services toll free at **1-866-231-0847**.

www.bcbswny.com/stateplans



BlueCross BlueShield of Western New York



Makena (hydroxyprogesterone caproate injection) Outpatient

CONTAINS CONFIDENTIAL PATIENT INFORMATION

Complete form in its entirety and fax to: Prior Authorization of Benefits Center at 1-844-493-9206

1. Patient information		2. Physician inf	2. Physician information									
Patient name:		Prescribing physi	cian:									
Patient ID #:			s:									
Patient DOB:			Physician phone #:									
Patient phone #:												
			ty:									
			nddress:									
3. Medication	4. Strength	5. Directions	6. Qty per 30 days	7. ICD code								
Makena (hydroxyprogesterone caproate injection)			Specify:									
8. Diagnosis:	1	1	1									
☐ Yes ☐ No Does the particle ☐ Yes ☐ No Does the particle ☐ Spontane ☐ Yes ☐ No Will injection ☐ Yes ☐ No Does the particle ☐ Yes ☐ Yes ☐ No Does The Particle ☐ Yes ☐ Yes ☐ No Does The Particle ☐ Yes ☐	he outcome of this requit t pregnant? ancy singleton (not twins tient have preterm labor	est.) s or other multiple)? with the current pregreterm delivery before Premature rupture of neen 16 and 36 weeks or or other than the currence of the currenc	nancy? 37 weeks gestation due to e nembranes									
Prescriber or authorized sign	nature	Da	te	· · · · · · · · · · · · · · · · · · ·								
Prior authorization of benefits physician. Only a treating phy plan for the detailed information the information provided is tru health of the patient. Note: Pa	sician can determine wha on regarding benefits, con e, accurate and complete	nt medications are appro aditions, limitations and a and the requested ser	opriate for a patient. Please re exclusions. The submitting provices are medically indicated a	fer to the applicable ovider certifies that and necessary to the								
Important note: You are not por are not enrolled to your practiculating mail, email, fax or ot	ctice. This applies to Prote	ected Health Information										

Market Applicability															
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	КҮ	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	Х	Χ	NA	NA	Х	NA	Χ	NA	Х	Χ	Χ	Χ	NA	NA	Χ

^{*}FHK- Florida Healthy Kids

Makena (hydroxyprogesterone caproate injection)

CG-DRUG-19

Override(s)	Approval Duration
Prior Authorization	6 months
Quantity limit	

Medications	Quantity Limit
Makena (hydroxyprogesterone caproate	May be subject to quantity limit
injection)	

APPROVAL CRITERIA

Requests for Makena (hydroxyprogesterone caproate injection) may be approved if the if the following criteria are met:

- I. Weekly injections of 17 alpha-hydroxyprogesterone caproate between 16 and 36 weeks of gestation **may be approved** in pregnant women who meet the following criteria:
 - A. A singleton pregnancy; AND
 - B. Absence of preterm labor within the current pregnancy; AND
 - C. A prior history of a preterm delivery before 37 weeks gestation due to either of the following:
 - 1. Spontaneous preterm labor; **OR**
 - 2. Premature rupture of membranes.

Requests for Makena (hydroxyprogesterone caproate injection) may **not** be approved for the following:

I. Progesterone therapy as a technique to prevent preterm labor may not be approved in pregnant women who do not meet the above criteria, or those with other risk factors for preterm delivery in the current pregnancy, including, but not limited, to: multiple gestation pregnancy, cervical cerclage, a uterine anomaly, positive tests for cervicovaginal fetal fibronectin, or preterm labor.

PAGE 1 of 2 04/20/2018

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability															
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	КҮ	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	Х	Χ	NA	NA	Х	NA	Χ	NA	Х	Χ	Χ	Χ	NA	NA	Χ

^{*}FHK- Florida Healthy Kids

II. Injections of 17 alpha-hydroxyprogesterone caproate in a home setting by or through a licensed home health agency may not be approved, except when criteria for home health services are met. (See CG-MED-23 - Home Health.)

State Specific Mandates										
State name	Date effective									
Louisiana		This policy does not apply.								
		6.13.1.2 Provision of injectable or vaginal								
		progesterone for every eligible pregnant woman with								
		a history of pre-term labor or a short cervix found in								
		the current pregnancy. The MCO shall not require								
		prior authorization of progesterone.								

Key References:

- 1. Additional press release information about the FDA new approval of Makena. February 4, 2011. Available at: <a href="http://www.prnewswire.com/news-releases/fda-approves-makena-the-first-and-only-treatment-to-reduce-the-risk-of-preterm-birth-in-women-with-a-singleton-pregnancy-who-have-a-history-of-singleton-spontaneous-preterm-birth-115271964.html. Accessed on September 15, 2015.
- United States Food and Drug Administration (FDA). Additional information about approval of Makena.
 February 4, 2011. Available at:
 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm242234.htm. Accessed on September 24, 2015